HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cance

Statistically significant survival improvements in MET-driven EGFR-mutated lung cancer post-TAGRISSO.